Nandita Joshi, MD
Internal Medicine · Englewood, NJNPI 1619991866
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 211 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 21.1% — the pattern of someone who eats at a lot of different presentations.
Across 211 payments — averaging $14.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$645
- Amgen$327
- AbbVie$258
- Novo Nordisk$213
- Merck$194
- Mannkind Corporation$170
- plus $1K from 32 others
Across 47 payments — averaging $5098.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$215K
- Shire North American Group Inc$21K
- Takeda Pharmaceuticals U.S.A., Inc.$4K
What the payments were for
- Food & beverage$3,053100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 53 | $645 |
| Amgen(2 entities) | 21 | $327 |
| AbbVie(2 entities) | 21 | $258 |
| Novo Nordisk | 18 | $213 |
| Merck | 15 | $194 |
| Mannkind Corporation | 8 | $170 |
| Lilly USA, LLC | 7 | $124 |
| Johnson & Johnson | 8 | $116 |
| Sanofi-aventis U.S. LLC | 5 | $82 |
| Grifols USA, LLC | 5 | $76 |
| Shire North American Group Inc | 5 | $71 |
| Pfizer | 4 | $66 |
| Boehringer Ingelheim | 5 | $65 |
| Corcept Therapeutics | 3 | $61 |
| Xeris Pharmaceuticals, Inc. | 3 | $57 |
| Exact Sciences | 2 | $48 |
| Mallinckrodt Hospital Products Inc. | 3 | $46 |
| Baxter Healthcare | 1 | $46 |
| Sanofi | 2 | $32 |
| Harmony Biosciences LLC | 1 | $29 |
| Medtronic | 1 | $29 |
| United Therapeutics Corporation | 2 | $29 |
| Teva Pharmaceuticals USA, Inc. | 2 | $28 |
| Amarin Pharma, Inc. | 2 | $26 |
| Alvogen Inc | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Vifor Pharma, Inc. | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| ANI Pharmaceuticals, Inc. | 1 | $15 |
| Abbott | 1 | $15 |
| Philips North America LLC | 1 | $15 |
| AstraZeneca | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| IBSA Pharma Inc. | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$3,053 in reported general payments places this provider in the 80th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 44 | $65,229 |
| JanuviaSitagliptin Phosphate | 45 | $42,281 |
| TrulicityDulaglutide | 16 | $29,025 |
| JardianceEmpagliflozin | 12 | $18,705 |
| FarxigaDapagliflozin Propanediol | 19 | $16,795 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $14,039 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $12,718 |
| LivaloPitavastatin Calcium | 12 | $11,095 |
| EliquisApixaban | 11 | $8,844 |
| Rosuvastatin Calcium | 383 | $6,208 |
| Atorvastatin Calcium | 450 | $4,355 |
| Ezetimibe | 109 | $3,139 |
| Olmesartan Medoxomil | 104 | $3,078 |
| Valsartan | 94 | $2,909 |
| Risedronate Sodium | 16 | $2,625 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $213 | $65,22944 claims |
| MerckJanuvia | $194 | $42,28145 claims |
| Lilly USA, LLCTrulicity | $124 | $29,02516 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $645 | $26,75735 claims |
| AstraZenecaFarxiga, Symbicort | $15 | $19,34730 claims |
| Boehringer IngelheimJardiance | $65 | $18,70512 claims |
| PfizerEliquis, Paxlovid | $66 | $10,27326 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $15 | $2,90994 claims |
| AbbVieSynthroid | $258 | $2,34159 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $15 | $2,316247 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Englewood
- David ShulkinMorristown$1.7M
- Howard UdermanLakewood$955K
- Darshi SunderamEast Orange$530K
- Annika DrongeEmerson$401K
- Stephen MarcellaNew Brunswick$331K
- Viju VijaysadanKinnelon$325K
- Mark MonaneWoodcliff Lake$268K
- Martin BedigianLivingston$240K
- Rameck HuntPlainsboro$217K
- Angel LazoSecaucus$195K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.